Compare Harmony Gold Mining Co. (HMY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Sana Biotechnology Inc — how do they compare? Harmony Gold Mining Co. trades at $15.32 (market cap $9.07B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Harmony Gold Mining Co. is far larger — about 10.4× Sana Biotechnology Inc's market cap, and Harmony Gold Mining Co. pays a 2.84% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HMY | SANA | |
|---|---|---|
Market Cap | $9.07B | $873.84M |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $5.92 |
52-Week Low | $12.61 | $2.68 |
Enterprise Value | $9.41B | $848.03M |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $15.325, up 4.61% today, but technical indicators signal a bearish trend with key resistance at $15. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, yet recent earnings missed expectations. Cash flow from operations improved to $15.65B in 2024, though 2025 projections show a net cash outflow. Analyst sentiment is mixed, with 70% hold ratings, reflecting caution amid gold price volatility and Fed rate hike concerns.
The outlook for HMY hinges on gold and copper price stability, with operational execution critical. Investment opportunities include a low P/E of 9.17 and a 4.06% dividend yield, but risks involve earnings misses, rising costs, and macroeconomic pressures. Investors should weigh strong profitability against sector headwinds and analyst skepticism.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
